grant
B-1a Cells and Acute Inflammation
Organization FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHLocation MANHASSET, UNITED STATESPosted 15 May 2026Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY2026ALI caused by sepsisARDSAcuteAcute Lung InjuryAcute Pulmonary InjuryAcute Respiratory DistressAcute Respiratory Distress SyndromeAdhesion MoleculeAdoptive TransferAdult ARDSAdult RDSAdult Respiratory Distress SyndromeAlveolarAmino AcidsApoptosisApoptosis PathwayAttenuatedB-Cell SubsetsB-Lymphocyte SubsetsBindingBinding SitesBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood capillariesCD162 antigenCD47CD47 AntigenCD47 GlycoproteinCD47 geneCD62LCD62L AntigensCSIFCSIF-10Cell Adhesion Molecule GeneCell Adhesion MoleculesCell BodyCell Communication and SignalingCell DeathCell SignalingCellsCellular MatrixCo-cultureCocultivationCocultureCoculture TechniquesCombining SiteCritical IllnessCritically IllCytokine Synthesis Inhibitory FactorCytoskeletal SystemCytoskeletonDa Nang LungDataDevelopmentDiseaseDisorderDoseDrug KineticsDysfunctionEatingEndothelial CellsEndotheliumExhibitsExudateFilopodiaFood IntakeFunctional disorderHLHRCHumanIL-10IL10IL10AImmunomodulationImpairmentIn VitroInflammationInflammatoryIntegrin-Associated ProteinInterleukin 10 PrecursorInterleukin-10Intracellular Communication and SignalingIschemiaIschemia-Reperfusion InjuryL-SelectinLAM-1LAM-1 Leukocyte Adhesion MoleculeLAM-1 geneLD-50LD50LECAM-1LECAM1LNHRLSELLYAM-1LYAM1Lethal Dose 50Leu-8 AntigenLifeLungLung InflammationLung Respiratory SystemLymphocyte Adhesion Molecule 1MER6MFR geneMFR proteinMYD-1Macrophage Fusion ReceptorMarrow NeutrophilMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMediatingMel-14 AntigenMetabolicMetabolic dysfunctionMiceMice MammalsModelingModern ManMolecularMolecular InteractionMorbidityMurineMusNamesNeutrophilic GranulocyteNeutrophilic LeukocyteOligopeptidesP-selectin glycoprotein ligand-1P-selectin ligand proteinP84PSGL-1PTPNS1PTPNS1 genePathway interactionsPatientsPeptidesPhagocytesPhagocytic CellPhagocytosisPhagosomesPharmacokineticsPharmacologyPhysiopathologyPlayPleuralPneumonitisPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPre-Clinical ModelPreclinical ModelsProcessProductionProgrammed Cell DeathProtein-Tyrosine Phosphatase, Nonreceptor Type, Substrate 1Public HealthPulmonary InflammationR-Series Research ProjectsR01 MechanismR01 ProgramReactive SiteReceptor SignalingRegulationReperfusion DamageReperfusion InjuryReperfusion TherapyResearchResearch GrantsResearch Project GrantsResearch ProjectsRoleSELL geneSHP Substrate 1SHPS-1 proteinSHPS1SIRP-Alpha-1SIRPASIRPalpha1SafetySelectin L GeneSepsisSeveritiesShock LungSignal PathwaySignal Regulatory Protein, Alpha Type, 1Signal TransductionSignal Transduction SystemsSignalingSourceSpleenSpleen Reticuloendothelial SystemStiff lungSupportive TherapySupportive careSurfaceSurface Antigen Identified by Monoclonal Antibody 1D8TQ-1TQ1 AntigenTestingTherapeuticTherapeutic InterventionTimeToxicologyTyrosine Phosphatase SHP Substrate 1Umbilical veinZ-DNA Binding Proteinafter sepsisafter septicamebocyteaminoacidattenuateattenuatesbiological signal transductioncapillarycell adhesion proteindeath due to sepsisdeath related to sepsisdevelopmentaleffective therapyeffective treatmentexperimentexperimental researchexperimental studyexperimentsfollowing sepsisfollowing septicimmune modulationimmune regulationimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimprovedin vivointervention therapyintracellular skeletoninventionlung microvascular endothelial cellslung vascular endothelial cellsmetabolic profilemitochondrial dysfunctionmortalitymortality associated with sepsismortality in sepsismouse modelmurine modelnamenamednamingnecrocytosisneutrophilnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathophysiologypathwaypost sepsispost septicpre-clinical developmentpreclinical developmentpreservationpreventpreventingpulmonarypulmonary microvascular endothelial cellspulmonary vascular endothelial cellsreperfusionsepsis associated ALIsepsis associated acute lung injurysepsis associated deathsepsis associated mortalitysepsis caused acute lung injurysepsis caused deathssepsis deathsepsis induced ALIsepsis induced acute lung injurysepsis induced deathsepsis induced mortalitysepsis lethalitysepsis mediated ALIsepsis mediated acute lung injurysepsis mortalitysepsis related acute lung injurysepsis related deathssepsis related mortalitysepticseptic deathseptic mortalitysevere sepsisseverely septicsialic acid binding Ig-like lectinsiglecsignal-regulatory proteinsocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentwet lung
Description preview
PROJECT SUMMARY: Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome,
are life-threatening conditions lacking effective treatments. ALI is frequently caused by sepsis or ischemia-
reperfusion (I/R) injury, both severe inflammatory disorders. In this project we plan to investigate the critical
role of B-1a cells,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click